The application discloses a compound as shown in a formula I, namely a novel wild-type EGFR and/or mutant EGFR kinase inhibitor, which can be used for treating non-small cell lung cancer by single use or combined use with other therapeutic agents. The compound as shown in the formula I in the application can be used for treating patients with drug-resistance non-small cell lung cancer carrying wild-type EGFR and/or EGFR-T790M mutant and/or EGFR-T858R mutant and/or EGFR-delE746_A750 mutant.